Synthetic Biologics, Inc.
(NYSE Amex Equities : SYN)

( )
SYN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
CELGCelgene Corporation
1.23%89.071.3%$885.86m
AMGNAmgen Inc.
0.09%191.491.2%$554.58m
GILDGilead Sciences, Inc.
0.72%65.490.9%$453.28m
ONCESpark Therapeutics, Inc.
-0.25%113.6711.2%$443.24m
BIIBBiogen Inc.
-0.58%323.761.3%$352.26m
REGNRegeneron Pharmaceuticals, Inc.
-0.15%406.992.6%$278.79m
ILMNIllumina, Inc.
1.61%310.703.5%$273.06m
BPTHBio-Path Holdings, Inc.
-9.32%25.20190.1%$257.65m
VRTXVertex Pharmaceuticals Incorporated
-3.05%181.761.9%$239.61m
SRPTSarepta Therapeutics, Inc.
-0.28%126.4715.4%$205.98m
EXASExact Sciences Corporation
-0.85%91.1525.3%$189.71m
ALXNAlexion Pharmaceuticals, Inc.
-0.43%132.942.0%$178.02m
AAgilent Technologies, Inc.
0.28%81.201.6%$151.29m
IONSIonis Pharmaceuticals, Inc.
0.11%79.618.3%$101.25m
BMRNBioMarin Pharmaceutical Inc.
-2.06%91.444.3%$95.59m

Company Profile

Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.